Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Day

Showing results (1011-1020 of 1,098) with videos related to

Pageof 110
Sort By:
Nature Communications|June 27, 2015
Glycan complexity dictates microbial resource allocation in the large intestineArtur Rogowski, Jonathon A Briggs, Jennifer C Mortimer, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Circulation. Cardiovascular Imaging|September 18, 2014
Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathyGabriella Captur, Luis R Lopes, Timothy J Mohun, et al.
European Heart Journal|September 15, 2012
Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studiesSonia Shah, Juan P Casas, Tom R Gaunt, et al.
Neuroimage|December 23, 2021
Filtering respiratory motion artifact from resting state fMRI data in infant and toddler populationsSydney Kaplan, Dominique Meyer, Oscar Miranda-Dominguez, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Journal of the American Heart Association|March 25, 2021
Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic CardiomyopathyMegan J Puckelwartz, Lorenzo L Pesce, Lisa M Dellefave-Castillo, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Nature|August 1, 2014
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrierMargarida A Santos, Robert B Faryabi, Aysegul V Ergen, et al.
Pageof 110

Showing results (1011-1020 of 1,098) with videos related to

Sort By:
Pageof 110
Nature Communications|June 27, 2015
Glycan complexity dictates microbial resource allocation in the large intestineArtur Rogowski, Jonathon A Briggs, Jennifer C Mortimer, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Circulation. Cardiovascular Imaging|September 18, 2014
Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathyGabriella Captur, Luis R Lopes, Timothy J Mohun, et al.
European Heart Journal|September 15, 2012
Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studiesSonia Shah, Juan P Casas, Tom R Gaunt, et al.
Neuroimage|December 23, 2021
Filtering respiratory motion artifact from resting state fMRI data in infant and toddler populationsSydney Kaplan, Dominique Meyer, Oscar Miranda-Dominguez, et al.
Open Heart|November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathyJennifer E Ho, Ling Shi, Sharlene M Day, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Journal of the American Heart Association|March 25, 2021
Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic CardiomyopathyMegan J Puckelwartz, Lorenzo L Pesce, Lisa M Dellefave-Castillo, et al.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Nature|August 1, 2014
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrierMargarida A Santos, Robert B Faryabi, Aysegul V Ergen, et al.
Pageof 110